Immuno-Oncology Market Poised for Substantial Growth, Driven by Advanced Technologies and Biomarker Integration
January 31, 2024 08:10 ET
|
Research and Markets
Dublin, Jan. 31, 2024 (GLOBE NEWSWIRE) -- The "Immuno-Oncology Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application,...
Tumor Infiltrating Lymphocytes Industry Projected to Reach $18.32 Billion by 2028 - Emerging Technologies, such as cytoDRIVE, and Strategic Alliances Propelling the Global Market Forward
January 23, 2024 09:43 ET
|
Research and Markets
Dublin, Jan. 23, 2024 (GLOBE NEWSWIRE) -- The "Tumor Infiltrating Lymphocytes Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering. Global Growth Driven by...
$7.25 Bn Antibody Fragments Markets - Global Industry Size, Share, Trends, Opportunity, and Forecasts to 2028
January 15, 2024 08:58 ET
|
Research and Markets
Dublin, Jan. 15, 2024 (GLOBE NEWSWIRE) -- The "Antibody Fragments Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F" report has been added to ...
Provectus Biopharmaceuticals Announces Notice of Allowance of First U.S. Patent of Rose Bengal Sodium for Use as Anticancer and Antiviral Vaccine Adjuvant
December 18, 2023 08:00 ET
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the United States Patent and Trademark Office (USPTO) has allowed patent application 17/488,430, titled...
Cancer Immunotherapy Market to Reach USD 251.41 Billion By 2032 | Emergen Research
December 11, 2023 07:48 ET
|
Emergen Research
Vancouver, Dec. 11, 2023 (GLOBE NEWSWIRE) -- The global Cancer Immunotherapy Market size was USD 84.53 Billion in 2021 and is expected to register a revenue CAGR of 10.4% during the forecast period,...
ImmunOs Therapeutics Presents Details of Novel Bispecific Anti-Tumor Molecules at ESMO Immuno-Oncology Congress 2023
December 11, 2023 04:00 ET
|
AKAMPION
HLA/SIRPa bispecifics targeting LILRB1/2 plus CD47 checkpoint receptorDesigned to target myeloid, NK and T cells and to be precisely directed to tumor sitesPotent in vitro anti-tumor efficacy...
Evaxion Presents Proof-of-Principle for Its Unique AI Model Predicting Responses to Cancer Immunotherapy
November 15, 2023 08:00 ET
|
Evaxion Biotech
Evaxion today presents a novel AI model designed to predict patient responses to standard-of-care cancer immunotherapyThe model demonstrates promising potential for improving patient outcomes,...
Provectus Biopharmaceuticals Provides Updated Data on Cancer Immunotherapy PV-10 for Metastatic Uveal Melanoma
November 13, 2023 08:00 ET
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today provided updated data from an ongoing Phase 1 clinical trial of investigational cancer immunotherapy PV-10 (rose bengal...
The Global Market for Bispecific Antibody Therapeutics Contract Manufacturing 2023-2030: Driven by Demand for Innovative Therapies and Promising Results Seen in Clinical Development
November 06, 2023 09:04 ET
|
Research and Markets
Dublin, Nov. 06, 2023 (GLOBE NEWSWIRE) -- The "Global Bispecific Antibody Therapeutics Contract Manufacturing Market 2023-2030" report has been added to ResearchAndMarkets.com's offering. The...
Provectus Biopharmaceuticals Announces Presentation of Preclinical PV-10 Vaccine Adjuvant Data at Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting
November 06, 2023 08:00 ET
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that preclinical data from ongoing research on the potential use of investigational cancer immunotherapy...